Interactions between aspirin and new generation P2Y12 receptor antagonists
Anti-platelet drugs are taken by millions of people to protect against heart attacks and strokes. Routinely, people at particular risk receive aspirin plus an ADP (P2Y12) receptor antagonist. This is because most trials of antiplatelet therapy have included initial treatment with aspirin alone followed by a second anti-platelet drug. Newer P2Y12 receptor antagonists that have stronger antiplatelet effects have never been tested without aspirin and it is not known if these newer drugs could be more effective without taking aspirin as well. This fellowship will study the ways in which anti-platelet drugs interact to block platelet function, and will study these interactions in healthy volunteers. These studies aim to reveal whether trials of the newer antiplatelet therapies without aspirin are justified.
Project details
| Grant amount | £252,665 |
|---|---|
| Grant type | Fellowships |
| Application type | Clinical Research Training Fellowship |
| Start Date | 03 April 2013 |
| Duration | 3 years |
| Reference | FS/12/53/29643 |
| Status | Complete |
